{"transactions":[{"id":4630735,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-10-05T21:12:51.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":4126,"price":57.1,"value":235594.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000028","document":"wk-form4_1791234769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1838139/000183813926000028/wk-form4_1791234769.xml","form_type":"4"}},{"id":4634547,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-10-01T00:33:24.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":642,"price":58.4055,"value":37496.331,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":79823,"source":{"system":"sec-edgar","filing":"0001683607-26-000016","document":"wk-form4_1790800401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000016/wk-form4_1790800401.xml","form_type":"4"}},{"id":4634554,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-10-01T00:32:14.000Z","date":"2026-09-28","kind":"sale","planned":true,"acquired":false,"shares":4126,"price":57.88,"value":238812.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."}],"balance_after":4126,"source":{"system":"sec-edgar","filing":"0001838139-26-000026","document":"wk-form4_1790800331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000026/wk-form4_1790800331.xml","form_type":"4"}},{"id":4626033,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-09-24T20:10:50.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":3927,"price":58.9261,"value":231402.7947,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":270401,"source":{"system":"sec-edgar","filing":"0001814238-26-000017","document":"wk-form4_1790280647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000017/wk-form4_1790280647.xml","form_type":"4"}},{"id":4626032,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-09-24T20:10:50.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":96073,"price":58.5148,"value":5621692.3804,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":274328,"source":{"system":"sec-edgar","filing":"0001814238-26-000017","document":"wk-form4_1790280647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000017/wk-form4_1790280647.xml","form_type":"4"}},{"id":681501,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-19T20:20:53.000Z","date":"2026-08-19","kind":"gift","planned":true,"acquired":false,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person made a charitable gift of Class A Ordinary Shares to Lehigh University."}],"balance_after":23200,"source":{"system":"sec-edgar","filing":"0001814238-26-000015","document":"wk-form4_1787170851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000015/wk-form4_1787170851.xml","form_type":"4"}},{"id":681500,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-19T20:20:53.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":100000,"price":59.9725,"value":5997250.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported sales were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.68 to $60.42 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":370401,"source":{"system":"sec-edgar","filing":"0001814238-26-000015","document":"wk-form4_1787170851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000015/wk-form4_1787170851.xml","form_type":"4"}},{"id":685581,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-17T21:01:12.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1772,"price":59.1415,"value":104798.738,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000027","document":"wk-form4_1787000470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000027/wk-form4_1787000470.xml","form_type":"4"}},{"id":685580,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-17T21:01:12.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":9230,"price":58.5864,"value":540752.472,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1772,"source":{"system":"sec-edgar","filing":"0001814876-26-000027","document":"wk-form4_1787000470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000027/wk-form4_1787000470.xml","form_type":"4"}},{"id":693129,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2026-08-07T21:24:36.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":662701,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001507678-26-000006","document":"wk-form4_1786137872.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000006/wk-form4_1786137872.xml","form_type":"4"}},{"id":693128,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:24:36.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":65216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1307820,"source":{"system":"sec-edgar","filing":"0001507678-26-000006","document":"wk-form4_1786137872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000006/wk-form4_1786137872.xml","form_type":"4"}},{"id":693127,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class E Ordinary Shares","published_at":"2026-08-07T21:24:13.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote (2)"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."}],"balance_after":1788777,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001814876-26-000025","document":"wk-form4_1786137851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000025/wk-form4_1786137851.xml","form_type":"4"}},{"id":693126,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:24:13.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":11002,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":11002,"source":{"system":"sec-edgar","filing":"0001814876-26-000025","document":"wk-form4_1786137851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000025/wk-form4_1786137851.xml","form_type":"4"}},{"id":693131,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:12:26.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":11002,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":470401,"source":{"system":"sec-edgar","filing":"0001814238-26-000013","document":"wk-form4_1786137144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000013/wk-form4_1786137144.xml","form_type":"4"}},{"id":693124,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2026-08-07T21:11:13.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":244412,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001838139-26-000024","document":"wk-form4_1786137071.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000024/wk-form4_1786137071.xml","form_type":"4"}},{"id":693123,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:11:13.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":8252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":8252,"source":{"system":"sec-edgar","filing":"0001838139-26-000024","document":"wk-form4_1786137071.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000024/wk-form4_1786137071.xml","form_type":"4"}},{"id":718147,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:10:26.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":9099,"price":55.8802,"value":508453.9398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.69 to $56.14 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000022","document":"wk-form4_1783023023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000022/wk-form4_1783023023.xml","form_type":"4"}},{"id":718169,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":600,"price":57.09,"value":34254.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.11 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718168,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":29400,"price":56.4423,"value":1659403.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $56.95 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40600,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718167,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":2554,"price":57.1031,"value":145841.3174,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.06 to $57.22 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":459399,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718166,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":97446,"price":56.5028,"value":5505971.8488,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":461953,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":722824,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-30T21:15:17.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":689,"price":54.3998,"value":37481.4622,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":79181,"source":{"system":"sec-edgar","filing":"0001683607-26-000014","document":"wk-form4_1782854114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000014/wk-form4_1782854114.xml","form_type":"4"}},{"id":726416,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:13:55.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":9098,"price":55.1843,"value":502066.7614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $55.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9099,"source":{"system":"sec-edgar","filing":"0001838139-26-000020","document":"wk-form4_1782422032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000020/wk-form4_1782422032.xml","form_type":"4"}},{"id":726431,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:11:53.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":117592,"price":54.4746,"value":6405777.1632,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":559399,"source":{"system":"sec-edgar","filing":"0001814238-26-000009","document":"wk-form4_1782421910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000009/wk-form4_1782421910.xml","form_type":"4"}},{"id":726430,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:11:53.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":32408,"price":54.107,"value":1753499.656,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":676991,"source":{"system":"sec-edgar","filing":"0001814238-26-000009","document":"wk-form4_1782421910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000009/wk-form4_1782421910.xml","form_type":"4"}},{"id":746329,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":40507,"kind":"person","name":"WEATHERMAN ELIZABETH H","position":1,"cik":"0001188681","reported_name":"WEATHERMAN ELIZABETH H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:29:04.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":13103,"source":{"system":"sec-edgar","filing":"0001188681-26-000003","document":"wk-form4_1780950541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000118868126000003/wk-form4_1780950541.xml","form_type":"4"}},{"id":746328,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":38736,"kind":"person","name":"Norden Gregory","position":1,"cik":"0001405104","reported_name":"Norden Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:28:03.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":196348,"source":{"system":"sec-edgar","filing":"0001405104-26-000004","document":"wk-form4_1780950480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000140510426000004/wk-form4_1780950480.xml","form_type":"4"}},{"id":746327,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":893,"kind":"person","name":"LOVE TED W","position":1,"cik":"0001188919","reported_name":"LOVE TED W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:27:04.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":58393,"source":{"system":"sec-edgar","filing":"0001188919-26-000008","document":"wk-form4_1780950421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000118891926000008/wk-form4_1780950421.xml","form_type":"4"}},{"id":746326,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":40506,"kind":"person","name":"HODGSON DAVID C","position":1,"cik":"0001193346","reported_name":"HODGSON DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:26:14.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the Reporting Person are held by him solely for the benefit of General Atlantic Service Company, L.P. The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares."}],"balance_after":37873,"source":{"system":"sec-edgar","filing":"0001193346-26-000004","document":"wk-form4_1780950371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000119334626000004/wk-form4_1780950371.xml","form_type":"4"}},{"id":746325,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:24:20.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":4545,"source":{"system":"sec-edgar","filing":"0001724605-26-000007","document":"wk-form4_1780950258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000172460526000007/wk-form4_1780950258.xml","form_type":"4"}},{"id":746324,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":15025,"kind":"person","name":"Engelbert Catherine M.","position":1,"cik":"0001796439","reported_name":"Engelbert Catherine M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:22:37.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":55673,"source":{"system":"sec-edgar","filing":"0001796439-26-000003","document":"wk-form4_1780950154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000179643926000003/wk-form4_1780950154.xml","form_type":"4"}},{"id":746323,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":40505,"kind":"person","name":"Coric Vlad","position":1,"cik":"0001704317","reported_name":"Coric Vlad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:21:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":15343,"source":{"system":"sec-edgar","filing":"0001704317-26-000006","document":"wk-form4_1780950084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000170431726000006/wk-form4_1780950084.xml","form_type":"4"}},{"id":746321,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:20:18.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":78492,"source":{"system":"sec-edgar","filing":"0001683607-26-000012","document":"wk-form4_1780950015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000012/wk-form4_1780950015.xml","form_type":"4"}},{"id":760279,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-28T20:48:21.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":64399,"price":53.9778,"value":3476116.3422,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000022","document":"wk-form4_1780001297.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000022/wk-form4_1780001297.xml","form_type":"4"}},{"id":768085,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-22T01:20:12.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":13684,"price":52.7505,"value":721837.842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.62 to $52.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18197,"source":{"system":"sec-edgar","filing":"0001838139-26-000018","document":"wk-form4_1779412810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000018/wk-form4_1779412810.xml","form_type":"4"}},{"id":777110,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-15T20:38:40.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":13684,"price":53.0647,"value":726137.3548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.25 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31881,"source":{"system":"sec-edgar","filing":"0001838139-26-000016","document":"wk-form4_1778877517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000016/wk-form4_1778877517.xml","form_type":"4"}},{"id":777109,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":38736,"kind":"person","name":"Norden Gregory","position":1,"cik":"0001405104","reported_name":"Norden Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-05-15T20:37:04.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":3045,"price":53,"value":161385.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12,  2026."}],"balance_after":191803,"source":{"system":"sec-edgar","filing":"0001405104-26-000002","document":"wk-form4_1778877421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000140510426000002/wk-form4_1778877421.xml","form_type":"4"}},{"id":786927,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:17:16.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":143821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1242604,"source":{"system":"sec-edgar","filing":"0001507678-26-000004","document":"wk-form4_1778275033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000004/wk-form4_1778275033.xml","form_type":"4"}},{"id":786926,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:14:41.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":24263,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":64399,"source":{"system":"sec-edgar","filing":"0001814876-26-000020","document":"wk-form4_1778274879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000020/wk-form4_1778274879.xml","form_type":"4"}},{"id":786943,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:12:19.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":24263,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":709399,"source":{"system":"sec-edgar","filing":"0001814238-26-000007","document":"wk-form4_1778274737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000007/wk-form4_1778274737.xml","form_type":"4"}},{"id":786925,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:10:50.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":18197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":45565,"source":{"system":"sec-edgar","filing":"0001838139-26-000014","document":"wk-form4_1778274645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000014/wk-form4_1778274645.xml","form_type":"4"}},{"id":796911,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-30T21:54:06.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49.7784,"value":93334.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40136,"source":{"system":"sec-edgar","filing":"0001814876-26-000018","document":"wk-form4_1777586044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/wk-form4_1777586044.xml","form_type":"4"}},{"id":796910,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-30T21:54:06.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":49.7784,"value":1638505.8144,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000018","document":"wk-form4_1777586044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/wk-form4_1777586044.xml","form_type":"4"}},{"id":819737,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-02T21:58:57.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":48.3318,"value":1590889.5288,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32916,"source":{"system":"sec-edgar","filing":"0001814876-26-000016","document":"wk-form4_1775167135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000016/wk-form4_1775167135.xml","form_type":"4"}},{"id":819736,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-02T21:58:57.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":48.3318,"value":90622.125,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42011,"source":{"system":"sec-edgar","filing":"0001814876-26-000016","document":"wk-form4_1775167135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000016/wk-form4_1775167135.xml","form_type":"4"}},{"id":824199,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-03-31T20:09:28.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":815,"price":45.977,"value":37471.255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":73947,"source":{"system":"sec-edgar","filing":"0001683607-26-000010","document":"wk-form4_1774987765.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000010/wk-form4_1774987765.xml","form_type":"4"}},{"id":828254,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-25T21:05:22.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":45.5287,"value":85366.3125,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43886,"source":{"system":"sec-edgar","filing":"0001814876-26-000014","document":"wk-form4_1774472720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000014/wk-form4_1774472720.xml","form_type":"4"}},{"id":828253,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-25T21:05:22.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":45.5287,"value":1498622.6892,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":65832,"source":{"system":"sec-edgar","filing":"0001814876-26-000014","document":"wk-form4_1774472720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000014/wk-form4_1774472720.xml","form_type":"4"}},{"id":861742,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":583,"price":47.0143,"value":27409.3369,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45761,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861741,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1292,"price":46.6747,"value":60303.7124,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46344,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861740,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":10429,"price":47.0145,"value":490314.2205,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":98748,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861739,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":22487,"price":46.6717,"value":1049506.5179,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":109177,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":882088,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-25T21:08:28.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":45.3165,"value":84968.4375,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47636,"source":{"system":"sec-edgar","filing":"0001814876-26-000010","document":"wk-form4_1772053705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000010/wk-form4_1772053705.xml","form_type":"4"}},{"id":882087,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-25T21:08:28.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":45.3165,"value":1491637.914,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":131664,"source":{"system":"sec-edgar","filing":"0001814876-26-000010","document":"wk-form4_1772053705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000010/wk-form4_1772053705.xml","form_type":"4"}},{"id":905320,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:03:47.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":157828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1098783,"source":{"system":"sec-edgar","filing":"0001507678-26-000002","document":"wk-form4_1771016624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000002/wk-form4_1771016624.xml","form_type":"4"}},{"id":905321,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:03:15.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":26626,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":49511,"source":{"system":"sec-edgar","filing":"0001814876-26-000008","document":"wk-form4_1771016592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000008/wk-form4_1771016592.xml","form_type":"4"}},{"id":905335,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:02:51.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":26626,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":685136,"source":{"system":"sec-edgar","filing":"0001814238-26-000002","document":"wk-form4_1771016568.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000002/wk-form4_1771016568.xml","form_type":"4"}},{"id":905317,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:02:26.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":19970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":27368,"source":{"system":"sec-edgar","filing":"0001838139-26-000012","document":"wk-form4_1771016542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000012/wk-form4_1771016542.xml","form_type":"4"}},{"id":919507,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":1087,"price":43.2928,"value":47059.2736,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22885,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919506,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":6195,"price":42.8431,"value":265413.0045,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23972,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919505,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":5843,"price":42.0839,"value":245896.2277,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30167,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919504,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":19076,"price":43.2928,"value":825853.4528,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164580,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919503,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":108759,"price":42.8432,"value":4659583.5888,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":183656,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919502,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":102581,"price":42.0839,"value":4317008.5459,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":292415,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":925352,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-02T21:59:30.000Z","date":"2026-01-30","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":41.0905,"value":821810.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.28 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000010","document":"wk-form4_1770069566.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000010/wk-form4_1770069566.xml","form_type":"4"}},{"id":931202,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-26T21:10:58.000Z","date":"2026-01-23","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":40.2555,"value":805110.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.56 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001838139-26-000008","document":"wk-form4_1769461855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000008/wk-form4_1769461855.xml","form_type":"4"}},{"id":932408,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-23T21:48:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":39.3484,"value":147556.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36010,"source":{"system":"sec-edgar","filing":"0001814876-26-000004","document":"wk-form4_1769204910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000004/wk-form4_1769204910.xml","form_type":"4"}},{"id":932407,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-23T21:48:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":39.3484,"value":2590383.8688,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":394996,"source":{"system":"sec-edgar","filing":"0001814876-26-000004","document":"wk-form4_1769204910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000004/wk-form4_1769204910.xml","form_type":"4"}},{"id":935436,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-20T22:00:25.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":39.5173,"value":790346.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.37 to $39.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001838139-26-000006","document":"wk-form4_1768946423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000006/wk-form4_1768946423.xml","form_type":"4"}},{"id":940107,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-13T22:37:44.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":40.7817,"value":815634.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.57 to $40.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001838139-26-000004","document":"wk-form4_1768343862.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000004/wk-form4_1768343862.xml","form_type":"4"}},{"id":946902,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:18:43.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":38.4157,"value":144058.875,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39760,"source":{"system":"sec-edgar","filing":"0001814876-26-000002","document":"wk-form4_1767734318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000002/wk-form4_1767734318.xml","form_type":"4"}},{"id":946901,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:18:43.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":38.4157,"value":2528982.3624,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":460828,"source":{"system":"sec-edgar","filing":"0001814876-26-000002","document":"wk-form4_1767734318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000002/wk-form4_1767734318.xml","form_type":"4"}},{"id":946900,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:17:52.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.4825,"value":769650.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.32 to $38.70 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001838139-26-000002","document":"wk-form4_1767734270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000002/wk-form4_1767734270.xml","form_type":"4"}},{"id":955257,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-01-02T21:06:43.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":967,"price":38.7418,"value":37463.3206,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":73132,"source":{"system":"sec-edgar","filing":"0001683607-26-000002","document":"wk-form4_1767388000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000002/wk-form4_1767388000.xml","form_type":"4"}},{"id":958248,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-29T21:58:27.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":39.319,"value":786380.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.22 to $39.41 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001838139-25-000014","document":"wk-form4_1767045504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000014/wk-form4_1767045504.xml","form_type":"4"}},{"id":961054,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-22T21:09:42.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.3791,"value":767582.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.22 to $38.57 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001838139-25-000012","document":"wk-form4_1766437779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000012/wk-form4_1766437779.xml","form_type":"4"}},{"id":962516,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-19T17:24:49.000Z","date":"2025-12-18","kind":"sale","planned":true,"acquired":false,"shares":30654,"price":38.4959,"value":1180053.3186,"ownership":{"direct":false,"nature":"By GWL 2014 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814899-25-000010","document":"wk-form4_1766183086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000010/wk-form4_1766183086.xml","form_type":"4"}},{"id":962515,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-19T17:24:49.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":79346,"price":38.5688,"value":3060280.0048,"ownership":{"direct":false,"nature":"By GWL 2014 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30654,"source":{"system":"sec-edgar","filing":"0001814899-25-000010","document":"wk-form4_1766183086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000010/wk-form4_1766183086.xml","form_type":"4"}},{"id":965122,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:43:16.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.321,"value":766420.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.24 to $38.40 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":140000,"source":{"system":"sec-edgar","filing":"0001838139-25-000010","document":"wk-form4_1766011394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000010/wk-form4_1766011394.xml","form_type":"4"}},{"id":965121,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:39:45.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":38.3601,"value":143850.375,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43510,"source":{"system":"sec-edgar","filing":"0001814876-25-000011","document":"wk-form4_1766011182.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000011/wk-form4_1766011182.xml","form_type":"4"}},{"id":965120,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:39:45.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":38.3601,"value":2525322.1032,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":526660,"source":{"system":"sec-edgar","filing":"0001814876-25-000011","document":"wk-form4_1766011182.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000011/wk-form4_1766011182.xml","form_type":"4"}},{"id":976266,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-09T22:00:36.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":18242,"price":39.1527,"value":714223.5534,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7398,"source":{"system":"sec-edgar","filing":"0001838139-25-000008","document":"wk-form4_1765317633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000008/wk-form4_1765317633.xml","form_type":"4"}},{"id":976265,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-09T22:00:36.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":23334,"price":39.1528,"value":913591.4352,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":160000,"source":{"system":"sec-edgar","filing":"0001838139-25-000008","document":"wk-form4_1765317633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000008/wk-form4_1765317633.xml","form_type":"4"}},{"id":979639,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-05T17:01:28.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":110000,"price":39.7728,"value":4375008.0,"ownership":{"direct":false,"nature":"By GWL 2014 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001814899-25-000008","document":"wk-form4_1764972084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000008/wk-form4_1764972084.xml","form_type":"4"}},{"id":981669,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:11:18.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":39.866,"value":149497.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47260,"source":{"system":"sec-edgar","filing":"0001814876-25-000009","document":"wk-form4_1764799875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000009/wk-form4_1764799875.xml","form_type":"4"}},{"id":981668,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:11:18.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":39.866,"value":2624458.512,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":592492,"source":{"system":"sec-edgar","filing":"0001814876-25-000009","document":"wk-form4_1764799875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000009/wk-form4_1764799875.xml","form_type":"4"}},{"id":981667,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:10:29.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":18242,"price":39.9,"value":727855.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":25640,"source":{"system":"sec-edgar","filing":"0001838139-25-000006","document":"wk-form4_1764799826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000006/wk-form4_1764799826.xml","form_type":"4"}},{"id":981666,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:10:29.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":23333,"price":39.9277,"value":931633.0241,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":183334,"source":{"system":"sec-edgar","filing":"0001838139-25-000006","document":"wk-form4_1764799826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000006/wk-form4_1764799826.xml","form_type":"4"}},{"id":987221,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":624,"price":37.9595,"value":23686.728,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":51010,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987220,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":3126,"price":38.6699,"value":120882.1074,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":51634,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987219,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":10686,"price":37.9604,"value":405644.8344,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":658324,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987218,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":55146,"price":38.6663,"value":2132291.7798,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":669010,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":991771,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":230,"price":39.0331,"value":8977.613,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991770,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":2770,"price":38.2858,"value":106051.666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.78 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":230,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991769,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":2470,"price":39.0067,"value":96346.549,"ownership":{"direct":false,"nature":"By GWL 2021 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991768,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":25530,"price":38.2789,"value":977260.317,"ownership":{"direct":false,"nature":"By GWL 2021 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2470,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991767,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":4599,"price":39.0071,"value":179393.6529,"ownership":{"direct":false,"nature":"By GWL 2020 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991766,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":47401,"price":38.2787,"value":1814448.6587,"ownership":{"direct":false,"nature":"By GWL 2020 G, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4599,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991765,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":4628,"price":39.0077,"value":180527.6356,"ownership":{"direct":false,"nature":"By GWL 2023 G HoldCo LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6084,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}},{"id":991764,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":71137,"kind":"person","name":"Lloyd George W.","position":1,"cik":"0001814899","reported_name":"Lloyd George W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Investments & CLO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-21T16:55:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":47798,"price":38.2788,"value":1829650.0824,"ownership":{"direct":false,"nature":"By GWL 2023 G HoldCo LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10712,"source":{"system":"sec-edgar","filing":"0001814899-25-000006","document":"wk-form4_1763762134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814899/000181489925000006/wk-form4_1763762134.xml","form_type":"4"}}],"next_cursor":"2025-11-21T16:55:37.000000Z,991764"}